Biomarin Pharmaceutical (BMRN) FY2015 results: revenue $890 million, up 18.8% on the year
Biomarin Pharmaceutical Inc. (BMRN) reported revenue of $890 million for fiscal 2015, the year ended 31 December 2015, up 18.8% on the year before. Net income was -$172 million, and diluted earnings per share $-1.07. The figures are the company's own, from the 10-K it filed with the SEC on 29 February 2016.
Revenue
$890 million
+18.8% on the year
FY2008FY2015
Operating margin
-12.4%
-12.4% a year earlier
FY2008FY2015
Net income
-$172 million
FY2008FY2015
Diluted EPS
-$1.07
FY2008FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
890
749
548
+18.8%
Cost of revenue
152
122
88.4
+24.3%
Gross profit
738
627
460
+17.7%
Gross margin
82.9%
83.7%
83.9%
Research and development
635
462
355
+37.5%
Selling, general and administrative
402
302
235
+33.1%
Operating income
-111
-92.9
-156
Operating margin
-12.4%
-12.4%
-28.4%
Interest expense
38.2
36.6
10.4
+4.4%
Pre-tax income
-155
-125
-177
Income tax
17.1
9.1
-0.1
+87.6%
Net income
-172
-134
-176
Net margin
-19.3%
-17.9%
-32.2%
Diluted EPS
-$1.07
-$0.92
-$1.28
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
-219
n/a
-59.6
Capital expenditure
228
117
65.1
+94.5%
Free cash flow
-447
n/a
-125
Free cash flow margin
-50.2%
n/a
-22.7%
Cash from investing
n/a
n/a
-299
Cash from financing
n/a
n/a
747
Depreciation and amortisation
47.2
45.9
36.0
+2.9%
Share-based compensation
112
86.4
64.4
+29.1%
Diluted shares, weighted
160m
146m
n/a
+9.3%
Shares outstanding at period end
162m
149m
143m
+8.3%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
2,401
1,528
1,341
+57.1%
Debt
662
643
656
+3.0%
Other liabilities
666
305
247
+118.7%
Total liabilities and equity
3,729
2,475
2,244
+50.7%
Fixed assets
704
524
319
+34.5%
Goodwill
197
54.3
54.3
+263.2%
Intangible assets
684
157
163
+336.8%
Investments
621
168
484
+270.7%
Cash and equivalents
397
875
569
-54.6%
Receivables
165
144
118
+14.2%
Inventory
272
199
163
+36.2%
Other assets
689
354
374
+94.7%
Total assets
3,729
2,475
2,244
+50.7%
10-K for the year ended 31 December 2015, filed 29 February 2016: the filing.